Ioannis Linas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ioannis Linas has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Joerg Zehetner
Department of Visceral Surgery, Hirslanden Clinic Beau-Site, Bern, Switzerland
4 shared publications - Ulf Kessler
Department of Pediatric Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
3 shared publications - Michael Doulberis
Department of Gastroenterology and Hepatology, Department of Medicine, Zurich University Hospital, 8091 Zurich, Switzerland
2 shared publications - Yannick Fringeli
Department of Visceral Surgery Hirslanden Clinic Beau-Site Bern Switzerland
2 shared publications - Yannick Fringeli
Department of Visceral Surgery, Hirslanden Clinic Beau-Site, Bern, Switzerland
2 shared publications Ahmed Madisch
Ernährungstherapie Basel, Basel, Schweiz
1 shared publication
Latest Publications
- Open Access
- 3 November 2026
- Published by Wolters Kluwer Health in Surgical Laparoscopy, Endoscopy & Percutaneous Techniques
Dysphagia, Safety, and Effectiveness of the RefluxStop Procedure in GERD Patients With Ineffective Esophageal Motility (IEM)
Background: Patients with gastroesophageal reflux disease (GERD) and ineffective esophageal motility (IEM) do not have optimal outcomes today. With standard-of-care antireflux procedures, dysphagia often worsens. RefluxStop treats acid reflux via a novel mechanism without encircling the esophagus. This study assesses dysphagia, safety, and efficacy of the RefluxStop procedure in subjects with IEM for up to 3 years. Methods: Clinical outcomes of RefluxStop in two IEM-GERD cohorts were evaluated retrospectively, in a combined investigator-initiated study at University Inselspital and Hirslanden Clinic Beau-Site in Switzerland. The primary outcome was incidence of dysphagia. The secondary outcomes included improvement in GERD Health-Related Quality of Life (GERD-HRQL), food passageway-related events, and serious procedure- or device-related adverse events (ie, SAEs, SADEs). Results: Sixty (n=60) consecutive subjects with IEM underwent the RefluxStop procedure, with a follow-up ranging between 3 and 47 months (mean 13 mo). Median (Q25-Q75) improvement in GERD-HRQL score was 89% (83% to 96%) with statistical significance ( P 50% improvement in GERD-HRQL score. Of the 40 subjects that reached 1-year follow-up, n=14/40 (35%) had dysphagia at baseline, which resolved or improved in 12 subjects and worsened in one. Thus, there was a significantly higher likelihood of dysphagia improvement compared with unchanged or worsened status ( P =0.013). Conclusions: RefluxStop surgical management for GERD was used in patients with IEM (n=60), a group which currently has no optimal treatment, and maintained favorable results for up to 3 years with excellent improvement of GERD-HRQL score (median 89%) and dysphagia (86% resolved or improved at 1y).
- 3 November 2026
- Published by Wolters Kluwer Health in Surgical Laparoscopy, Endoscopy & Percutaneous Techniques
Open AccessDysphagia, Safety, and Effectiveness of the RefluxStop Procedure in GERD Patients With Ineffective Esophageal Motility (IEM)
Background: Patients with gastroesophageal reflux disease (GERD) and ineffective esophageal motility (IEM) do not have optimal outcomes today. With standard-of-care antireflux procedures, dysphagia often worsens. RefluxStop treats acid reflux via a novel mechanism without encircling the esophagus. This study assesses dysphagia, safety, and efficacy of the RefluxStop procedure in subjects with IEM for up to 3 years. Methods: Clinical outcomes of RefluxStop in two IEM-GERD cohorts were evaluated retrospectively, in a combined investigator-initiated study at University Inselspital and Hirslanden Clinic Beau-Site in Switzerland. The primary outcome was incidence of dysphagia. The secondary outcomes included improvement in GERD Health-Related Quality of Life (GERD-HRQL), food passageway-related events, and serious procedure- or device-related adverse events (ie, SAEs, SADEs). Results: Sixty (n=60) consecutive subjects with IEM underwent the RefluxStop procedure, with a follow-up ranging between 3 and 47 months (mean 13 mo). Median (Q25-Q75) improvement in GERD-HRQL score was 89% (83% to 96%) with statistical significance ( P 50% improvement in GERD-HRQL score. Of the 40 subjects that reached 1-year follow-up, n=14/40 (35%) had dysphagia at baseline, which resolved or improved in 12 subjects and worsened in one. Thus, there was a significantly higher likelihood of dysphagia improvement compared with unchanged or worsened status ( P =0.013). Conclusions: RefluxStop surgical management for GERD was used in patients with IEM (n=60), a group which currently has no optimal treatment, and maintained favorable results for up to 3 years with excellent improvement of GERD-HRQL score (median 89%) and dysphagia (86% resolved or improved at 1y).
- Open Access
- 1 July 2025
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 155 (7) , 4191
Effectiveness and safety of first-line empirical Helicobacter pylori eradication regimens in Switzerland: an interim analysis from a prospective multicentre registry (Hp-EuReg)
BACKGROUND: Helicobacter pylori infection remains prevalent globally. Despite the relatively low reported prevalence in Switzerland, the actual burden is thought to be higher, primarily due to migration. To date, limited evidence is available regarding the effectiveness of Helicobacter pylori eradication therapy in Switzerland. METHODS: This is a sub-study of the European Registry on Helicobacter pylori Management (Hp-EuReg), an international, multicentre, prospective, non-interventional registry of the routine clinical practice of gastroenterologists. All adult patients with Helicobacter pylori infections were systematically registered in the AEG-REDCap electronic case report form from 2013 to December 2023. Swiss data were analysed for effectiveness on a modified intention-to-treat (mITT) basis, assessing both the therapy duration and the acid inhibition administered with treatment. RESULTS: A total of 486 adult patients diagnosed with Helicobacter pylori infection were evaluated. Of these, 428 (88%) were treatment-naïve patients. A total of 283 patients with available follow-up were evaluated for effectiveness, adverse events, and compliance. Two first-line regimens accounted for over 90% of cases: amoxicillin-clarithromycin triple therapy in 49% and 10-day single-capsule bismuth quadruple therapy (containing metronidazole-tetracycline-bismuth) in 42%. The overall modified intention-to-treat effectiveness was 92%, achieving 91% in the low-dose proton pump inhibitor (PPI) group (20 mg omeprazole equivalent twice daily) and 96% in the group receiving high-dose (80 mg omeprazole equivalent twice daily) proton pump inhibitors. The lowest effectiveness (82%, 28/34 cases) was reported with 7-day amoxicillin-clarithromycin triple therapy, while the highest effectiveness (97%, 100/103 cases) was achieved with single-capsule bismuth quadruple therapy. Regarding safety, the overall incidence of at least one adverse event was 8.5%, and no serious adverse events were reported. CONCLUSIONS: In Switzerland, 10-day single-capsule bismuth quadruple therapy with metronidazole, tetracycline, and bismuth demonstrated high eradication success (>90%) and represents a promising empirical first-line treatment option in routine clinical practice.
- 1 July 2025
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 155 (7) , 4191
Open AccessEffectiveness and safety of first-line empirical Helicobacter pylori eradication regimens in Switzerland: an interim analysis from a prospective multicentre registry (Hp-EuReg)
BACKGROUND: Helicobacter pylori infection remains prevalent globally. Despite the relatively low reported prevalence in Switzerland, the actual burden is thought to be higher, primarily due to migration. To date, limited evidence is available regarding the effectiveness of Helicobacter pylori eradication therapy in Switzerland. METHODS: This is a sub-study of the European Registry on Helicobacter pylori Management (Hp-EuReg), an international, multicentre, prospective, non-interventional registry of the routine clinical practice of gastroenterologists. All adult patients with Helicobacter pylori infections were systematically registered in the AEG-REDCap electronic case report form from 2013 to December 2023. Swiss data were analysed for effectiveness on a modified intention-to-treat (mITT) basis, assessing both the therapy duration and the acid inhibition administered with treatment. RESULTS: A total of 486 adult patients diagnosed with Helicobacter pylori infection were evaluated. Of these, 428 (88%) were treatment-naïve patients. A total of 283 patients with available follow-up were evaluated for effectiveness, adverse events, and compliance. Two first-line regimens accounted for over 90% of cases: amoxicillin-clarithromycin triple therapy in 49% and 10-day single-capsule bismuth quadruple therapy (containing metronidazole-tetracycline-bismuth) in 42%. The overall modified intention-to-treat effectiveness was 92%, achieving 91% in the low-dose proton pump inhibitor (PPI) group (20 mg omeprazole equivalent twice daily) and 96% in the group receiving high-dose (80 mg omeprazole equivalent twice daily) proton pump inhibitors. The lowest effectiveness (82%, 28/34 cases) was reported with 7-day amoxicillin-clarithromycin triple therapy, while the highest effectiveness (97%, 100/103 cases) was achieved with single-capsule bismuth quadruple therapy. Regarding safety, the overall incidence of at least one adverse event was 8.5%, and no serious adverse events were reported. CONCLUSIONS: In Switzerland, 10-day single-capsule bismuth quadruple therapy with metronidazole, tetracycline, and bismuth demonstrated high eradication success (>90%) and represents a promising empirical first-line treatment option in routine clinical practice.
- Open Access
- 1 July 2024
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 154 (7) , 3365
Exploring the feasibility and safety of laparoscopic anti-reflux surgery with the new RefluxStop™ device: a retrospective cohort study of 40 patients
AIMS OF THE STUDY: Anti-reflux surgery aims to restore the anti-reflux barrier and reduce the retrograde flow of stomach contents. However, traditional surgical techniques generally involve some degree of encircling of the oesophagus, which can result in adverse effects such as dysphagia and the inability to belch or vomit. Based on the first published results, a novel surgical technique – with the RefluxStop™ device – appears promising for treating gastroesophageal reflux disease (GERD) with minimal postoperative dysphagia. This study describes the initial clinical experience with this procedure in a cohort of patients with chronic gastroesophageal reflux disease to evaluate its feasibility and safety in clinical practice. METHODS: This retrospective cohort study examined the first 40 patients who underwent laparoscopic anti-reflux surgery with the RefluxStop™ device at a private hospital in Switzerland. The procedure involves implanting a nonactive device on the outside of the gastric fundus to stabilise a narrow oesophagogastric plication. Feasibility was assessed based on the proportion of patients in whom the device could be successfully implanted, with a discussion of the operative details. Intraoperative and postoperative complications, adverse effects, and changes in gastroesophageal reflux disease-related quality of life (GERD-HRQL questionnaire) are also reported. RESULTS: Between May 2020 and April 2022, 40 patients underwent elective surgery for laparoscopic hiatal hernia repair and RefluxStop™ device implantation. All patients had typical symptoms of gastroesophageal reflux disease, such as heartburn and regurgitation; 20 (50%) had preoperative dysphagia. Laparoscopic surgery was feasible in all patients except one who required laparotomy due to adhesions and associated bleeding when accessing the abdomen. The median operating time was 57.5 minutes (interquartile range = 51.75–64.25 minutes) with no device-related intraoperative or postoperative complications. All patients were imaged one day and three months postoperative, confirming the correct placement of the device. Reflux symptoms (heartburn and acid regurgitation) were significantly improved in all patients at three months (p <0.0001). CONCLUSION: These preliminary results support the feasibility and safety of introducing this novel laparoscopic anti-reflux surgical treatment option in clinical practice.
- 1 July 2024
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 154 (7) , 3365
Open AccessExploring the feasibility and safety of laparoscopic anti-reflux surgery with the new RefluxStop™ device: a retrospective cohort study of 40 patients
AIMS OF THE STUDY: Anti-reflux surgery aims to restore the anti-reflux barrier and reduce the retrograde flow of stomach contents. However, traditional surgical techniques generally involve some degree of encircling of the oesophagus, which can result in adverse effects such as dysphagia and the inability to belch or vomit. Based on the first published results, a novel surgical technique – with the RefluxStop™ device – appears promising for treating gastroesophageal reflux disease (GERD) with minimal postoperative dysphagia. This study describes the initial clinical experience with this procedure in a cohort of patients with chronic gastroesophageal reflux disease to evaluate its feasibility and safety in clinical practice. METHODS: This retrospective cohort study examined the first 40 patients who underwent laparoscopic anti-reflux surgery with the RefluxStop™ device at a private hospital in Switzerland. The procedure involves implanting a nonactive device on the outside of the gastric fundus to stabilise a narrow oesophagogastric plication. Feasibility was assessed based on the proportion of patients in whom the device could be successfully implanted, with a discussion of the operative details. Intraoperative and postoperative complications, adverse effects, and changes in gastroesophageal reflux disease-related quality of life (GERD-HRQL questionnaire) are also reported. RESULTS: Between May 2020 and April 2022, 40 patients underwent elective surgery for laparoscopic hiatal hernia repair and RefluxStop™ device implantation. All patients had typical symptoms of gastroesophageal reflux disease, such as heartburn and regurgitation; 20 (50%) had preoperative dysphagia. Laparoscopic surgery was feasible in all patients except one who required laparotomy due to adhesions and associated bleeding when accessing the abdomen. The median operating time was 57.5 minutes (interquartile range = 51.75–64.25 minutes) with no device-related intraoperative or postoperative complications. All patients were imaged one day and three months postoperative, confirming the correct placement of the device. Reflux symptoms (heartburn and acid regurgitation) were significantly improved in all patients at three months (p <0.0001). CONCLUSION: These preliminary results support the feasibility and safety of introducing this novel laparoscopic anti-reflux surgical treatment option in clinical practice.
- Open Access
- 29 February 2024
- Published by Wolters Kluwer Health in Surgical Laparoscopy, Endoscopy & Percutaneous Techniques
- Vol. 34 (2) , 143-149
Laparoscopic Large Hiatal Hernia Repair With RefluxStop: Outcomes of Six Months Follow-up in Thirty Patients
Objective: The antireflux surgical technique with the RefluxStop device is one of the latest approaches to treating patients with gastroesophageal reflux disease (GERD). The aim of this study was to assess the safety and feasibility of laparoscopic hiatal hernia (HH) repair with the RefluxStop device in patients with GERD and concurrent large HH (≥4 cm). Patients and Methods: A retrospective chart review was performed for the first 30 patients with a large HH who consented and underwent HH surgery with the RefluxStop device. The operative technique and outcomes were evaluated to assess safety and feasibility, HH recurrence, dysphagia, and patient satisfaction. Results: Between May 2020 and April 2022, 30 patients underwent laparoscopic HH repair with the RefluxStop device. All patients had typical symptoms of GERD, such as heartburn and regurgitation, and 15 patients (50%) had preoperative dysphagia. Median HH size was 5 cm (interquartile range, 4 to 5). Median operating time was 56 minutes (interquartile range, 52 to 63), with no intra and postoperative complications related to the device. One patient required laparotomy due to adhesions and associated bleeding when accessing the abdomen. All patients had postoperative imaging (video fluoroscopy) on postoperative day 1 and at 3 months, confirming the correct location of the RefluxStop device. One patient (3.3%) needed postoperative balloon dilatation due to severe dysphagia. Reflux symptoms (heartburn and acid regurgitation) resolved significantly in all patients (P < 0.001) at 6 months. One episode of recurrence of HH (3.3%) occurred during the follow-up period of 6 months. Conclusion: This study demonstrates the short-term safety and feasibility of laparoscopic HH repair with the RefluxStop device in patients with large HH, with a low rate of postoperative dysphagia and subsequent improvement or resolution of reflux symptoms in all patients.
- 29 February 2024
- Published by Wolters Kluwer Health in Surgical Laparoscopy, Endoscopy & Percutaneous Techniques
- Vol. 34 (2) , 143-149
Open AccessLaparoscopic Large Hiatal Hernia Repair With RefluxStop: Outcomes of Six Months Follow-up in Thirty Patients
Objective: The antireflux surgical technique with the RefluxStop device is one of the latest approaches to treating patients with gastroesophageal reflux disease (GERD). The aim of this study was to assess the safety and feasibility of laparoscopic hiatal hernia (HH) repair with the RefluxStop device in patients with GERD and concurrent large HH (≥4 cm). Patients and Methods: A retrospective chart review was performed for the first 30 patients with a large HH who consented and underwent HH surgery with the RefluxStop device. The operative technique and outcomes were evaluated to assess safety and feasibility, HH recurrence, dysphagia, and patient satisfaction. Results: Between May 2020 and April 2022, 30 patients underwent laparoscopic HH repair with the RefluxStop device. All patients had typical symptoms of GERD, such as heartburn and regurgitation, and 15 patients (50%) had preoperative dysphagia. Median HH size was 5 cm (interquartile range, 4 to 5). Median operating time was 56 minutes (interquartile range, 52 to 63), with no intra and postoperative complications related to the device. One patient required laparotomy due to adhesions and associated bleeding when accessing the abdomen. All patients had postoperative imaging (video fluoroscopy) on postoperative day 1 and at 3 months, confirming the correct location of the RefluxStop device. One patient (3.3%) needed postoperative balloon dilatation due to severe dysphagia. Reflux symptoms (heartburn and acid regurgitation) resolved significantly in all patients (P < 0.001) at 6 months. One episode of recurrence of HH (3.3%) occurred during the follow-up period of 6 months. Conclusion: This study demonstrates the short-term safety and feasibility of laparoscopic HH repair with the RefluxStop device in patients with large HH, with a low rate of postoperative dysphagia and subsequent improvement or resolution of reflux symptoms in all patients.
- Open Access
- 29 February 2024
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 409 (1) , 1-9
Short-term results of laparoscopic anti-reflux surgery with the RefluxStop device in patients with gastro-esophageal reflux disease and ineffective esophageal motility
Purpose: In gastro-esophageal reflux disease (GERD) requiring surgical treatment, concomitant ineffective esophageal motility (IEM) is a decisive factor in surgical planning, due to concern regarding dysphagia. Anti-reflux surgery with the RefluxStop device is a promising technique. We assessed initial feasibility and clinical outcomes of RefluxStop surgery in patients with GERD and IEM. Methods: Retrospective analysis of patients with GERD, hiatal hernia (HH), and IEM, who underwent surgery with RefluxStop at our institution and achieved 12-month follow-up. Technique feasibility was assessed, in addition to symptom resolution (GERD-HRQL questionnaire), adverse events, HH recurrence, dysphagia, and patient satisfaction. Placement of the device was confirmed by video fluoroscopy on postoperative day 1, and at 3 and 12 months. Results: Between June 2020 and November 2022, 20 patients with IEM underwent surgery with RefluxStop and completed 12-month follow-up. All patients reported typical symptoms of GERD, and 12 had preoperative dysphagia. The median HH length was 4.5 cm (IQR, 3.75–5). The median operating time was 59.5 min (IQR, 50.25–64) with no implant-related intra- or postoperative complications. No HH recurrence was observed. One patient reported persistent left-sided thoracic pain at 11 months post-surgery, which required diagnostic laparoscopy and adhesiolysis. Three patients reported severe postoperative dysphagia: balloon dilatation was performed towards resolution. The mean GERD-HRQL scores improved (from 40.7 at baseline to 4.8 at 3 months and 5.7 at 12 months (p <0.001)). Conclusion: RefluxStop surgery was feasible and offered effective treatment for this group of patients with GERD and IEM. All patients had complete resolution or significant improvement of GERD symptoms, and 90% of them were satisfied with their quality of life 1 year after surgery.
- 29 February 2024
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 409 (1) , 1-9
Open AccessShort-term results of laparoscopic anti-reflux surgery with the RefluxStop device in patients with gastro-esophageal reflux disease and ineffective esophageal motility
Purpose: In gastro-esophageal reflux disease (GERD) requiring surgical treatment, concomitant ineffective esophageal motility (IEM) is a decisive factor in surgical planning, due to concern regarding dysphagia. Anti-reflux surgery with the RefluxStop device is a promising technique. We assessed initial feasibility and clinical outcomes of RefluxStop surgery in patients with GERD and IEM. Methods: Retrospective analysis of patients with GERD, hiatal hernia (HH), and IEM, who underwent surgery with RefluxStop at our institution and achieved 12-month follow-up. Technique feasibility was assessed, in addition to symptom resolution (GERD-HRQL questionnaire), adverse events, HH recurrence, dysphagia, and patient satisfaction. Placement of the device was confirmed by video fluoroscopy on postoperative day 1, and at 3 and 12 months. Results: Between June 2020 and November 2022, 20 patients with IEM underwent surgery with RefluxStop and completed 12-month follow-up. All patients reported typical symptoms of GERD, and 12 had preoperative dysphagia. The median HH length was 4.5 cm (IQR, 3.75–5). The median operating time was 59.5 min (IQR, 50.25–64) with no implant-related intra- or postoperative complications. No HH recurrence was observed. One patient reported persistent left-sided thoracic pain at 11 months post-surgery, which required diagnostic laparoscopy and adhesiolysis. Three patients reported severe postoperative dysphagia: balloon dilatation was performed towards resolution. The mean GERD-HRQL scores improved (from 40.7 at baseline to 4.8 at 3 months and 5.7 at 12 months (p <0.001)). Conclusion: RefluxStop surgery was feasible and offered effective treatment for this group of patients with GERD and IEM. All patients had complete resolution or significant improvement of GERD symptoms, and 90% of them were satisfied with their quality of life 1 year after surgery.
- 6 July 2023
- Published by Elsevier in Gastroenterology
- Vol. 164 (6)
Mo1339 GERD PATIENTS WITH INEFFECTIVE ESOPHAGEAL MOTILITY: 12-MONTH FOLLOW-UP RESULTS OF LAPAROSCOPIC HIATAL HERNIA REPAIR WITH REFLUXSTOP
- 6 July 2023
- Published by Elsevier in Gastroenterology
- Vol. 164 (6)
Mo1339 GERD PATIENTS WITH INEFFECTIVE ESOPHAGEAL MOTILITY: 12-MONTH FOLLOW-UP RESULTS OF LAPAROSCOPIC HIATAL HERNIA REPAIR WITH REFLUXSTOP
- Open Access
- 14 June 2023
- Published by MDPI AG in Microorganisms
- Vol. 11 (6) , 1581
Association between Helicobacter pylori Infection and Nasal Polyps: A Systematic Review and Meta-Analysis
Background: Helicobacter pylori (H. pylori) has definite or possible associations with multiple local and distant manifestations. H. pylori has been isolated from multiple sites throughout the body, including the nose. Clinical non-randomized studies with H. pylori report discrepant data regarding the association between H. pylori infection and nasal polyps. The aim of this first systematic review and meta-analysis was the assessment of the strength of the association between H. pylori infection and incidence of nasal polyps. Methods: We performed an electronic search in the three major medical databases, namely PubMed, EMBASE and Cochrane, to extract and analyze data as per PRISMA guidelines. Results: Out of 57 articles, 12 studies were graded as good quality for analysis. Male-to-female ratio was 2:1, and age ranged between 17–78 years. The cumulative pooled rate of H. pylori infection in the nasal polyp group was 32.3% (controls 17.8%). The comparison between the two groups revealed a more significant incidence of H. pylori infection among the nasal polyp group (OR 4.12), though with high heterogeneity I2 = 66%. Subgroup analysis demonstrated that in European studies, the prevalence of H. pylori infection among the nasal polyp group was significantly higher than in controls, yielding null heterogeneity. Subgroup analysis based on immunohistochemistry resulted in null heterogeneity with preserving a statistically significant difference in H. pylori infection prevalence between the groups. Conclusion: The present study revealed a positive association between H. pylori infection and nasal polyps.
- 14 June 2023
- Published by MDPI AG in Microorganisms
- Vol. 11 (6) , 1581
Open AccessAssociation between Helicobacter pylori Infection and Nasal Polyps: A Systematic Review and Meta-Analysis
Background: Helicobacter pylori (H. pylori) has definite or possible associations with multiple local and distant manifestations. H. pylori has been isolated from multiple sites throughout the body, including the nose. Clinical non-randomized studies with H. pylori report discrepant data regarding the association between H. pylori infection and nasal polyps. The aim of this first systematic review and meta-analysis was the assessment of the strength of the association between H. pylori infection and incidence of nasal polyps. Methods: We performed an electronic search in the three major medical databases, namely PubMed, EMBASE and Cochrane, to extract and analyze data as per PRISMA guidelines. Results: Out of 57 articles, 12 studies were graded as good quality for analysis. Male-to-female ratio was 2:1, and age ranged between 17–78 years. The cumulative pooled rate of H. pylori infection in the nasal polyp group was 32.3% (controls 17.8%). The comparison between the two groups revealed a more significant incidence of H. pylori infection among the nasal polyp group (OR 4.12), though with high heterogeneity I2 = 66%. Subgroup analysis demonstrated that in European studies, the prevalence of H. pylori infection among the nasal polyp group was significantly higher than in controls, yielding null heterogeneity. Subgroup analysis based on immunohistochemistry resulted in null heterogeneity with preserving a statistically significant difference in H. pylori infection prevalence between the groups. Conclusion: The present study revealed a positive association between H. pylori infection and nasal polyps.
- Open Access
- 1 April 2023
- Published by Hogrefe Publishing Group in Praxis
- Vol. 112 (5-6) , 304-316
Häufige Magen-Darm-Beschwerden: Management der funktionellen Dyspepsie und des Reizdarm-Syndroms in der Praxis
Zusammenfassung: Funktionelle Dyspepsie (FD) und Reizdarm-Syndrom (RDS), zwei häufige gastro-intestinale Entitäten mit überlappenden Symptomen, sollten nach den Rom-IV-Kriterien diagnostiziert werden. Dabei handelt es sich um eines oder mehrere der folgenden Symptome: bei FD um postprandiales Völlegefühl, frühes Sättigungsgefühl, Schmerzen oder Brennen epigastral; bei RDS um rezidivierende abdominale Schmerzen jeweils assoziiert mit Defäkation, Veränderungen der Stuhlfrequenz oder der Stuhlform. Zum Ausschluss struktureller Krankheiten ist auf Alarmsymptome zu achten. Für die Therapie bewährt sich bei beiden Krankheiten ein Stufenschema. Stufe 1: Arzt-Patienten-Gespräch mit Erläuterung von Diagnose und Prognose sowie Klärung der Therapieziele; Optimierung des Lebensstils; Einsatz von Phytotherapeutika; Stufe 2: Symptomorientierte Medikamente: bei FD Protonenpumpenhemmer bzw. Prokinetika; bei RDS Spasmolytika, Sekretagoga, Laxanzien, Gallensäurebinder, Antidiarrhoika, Antibiotika, Probiotika; Stufe. 3: viszerale Analgetika (Antidepressiva).
- 1 April 2023
- Published by Hogrefe Publishing Group in Praxis
- Vol. 112 (5-6) , 304-316
Open AccessHäufige Magen-Darm-Beschwerden: Management der funktionellen Dyspepsie und des Reizdarm-Syndroms in der Praxis
Zusammenfassung: Funktionelle Dyspepsie (FD) und Reizdarm-Syndrom (RDS), zwei häufige gastro-intestinale Entitäten mit überlappenden Symptomen, sollten nach den Rom-IV-Kriterien diagnostiziert werden. Dabei handelt es sich um eines oder mehrere der folgenden Symptome: bei FD um postprandiales Völlegefühl, frühes Sättigungsgefühl, Schmerzen oder Brennen epigastral; bei RDS um rezidivierende abdominale Schmerzen jeweils assoziiert mit Defäkation, Veränderungen der Stuhlfrequenz oder der Stuhlform. Zum Ausschluss struktureller Krankheiten ist auf Alarmsymptome zu achten. Für die Therapie bewährt sich bei beiden Krankheiten ein Stufenschema. Stufe 1: Arzt-Patienten-Gespräch mit Erläuterung von Diagnose und Prognose sowie Klärung der Therapieziele; Optimierung des Lebensstils; Einsatz von Phytotherapeutika; Stufe 2: Symptomorientierte Medikamente: bei FD Protonenpumpenhemmer bzw. Prokinetika; bei RDS Spasmolytika, Sekretagoga, Laxanzien, Gallensäurebinder, Antidiarrhoika, Antibiotika, Probiotika; Stufe. 3: viszerale Analgetika (Antidepressiva).
- 1 October 2017
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 199 (7) , 2570-2584
The Stimulation of Macrophages with TLR Ligands Supports Increased IL-19 Expression in Inflammatory Bowel Disease Patients and in Colitis Models
IL-19, a member of the IL-10 cytokine family that signals through the IL-20 receptor type I (IL-20Rα:IL-20Rβ), is a cytokine whose function is not completely known. In this article, we show that the expression of IL19 in biopsies of patients with active ulcerative colitis was increased compared with patients with quiescent ulcerative colitis and that colitis was attenuated in IL-19–deficient mice. The disruption of the epithelial barrier with dextran sodium sulfate leads to increased IL-19 expression. Attenuated colitis in IL-19–deficient animals was associated with reduced numbers of IL-6–producing macrophages in the inflamed colonic lamina propria. Microbial-driven expression of IL-19 by intestinal macrophages may contribute to the pathogenesis of inflammatory bowel disease.
- 1 October 2017
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 199 (7) , 2570-2584
The Stimulation of Macrophages with TLR Ligands Supports Increased IL-19 Expression in Inflammatory Bowel Disease Patients and in Colitis Models
IL-19, a member of the IL-10 cytokine family that signals through the IL-20 receptor type I (IL-20Rα:IL-20Rβ), is a cytokine whose function is not completely known. In this article, we show that the expression of IL19 in biopsies of patients with active ulcerative colitis was increased compared with patients with quiescent ulcerative colitis and that colitis was attenuated in IL-19–deficient mice. The disruption of the epithelial barrier with dextran sodium sulfate leads to increased IL-19 expression. Attenuated colitis in IL-19–deficient animals was associated with reduced numbers of IL-6–producing macrophages in the inflamed colonic lamina propria. Microbial-driven expression of IL-19 by intestinal macrophages may contribute to the pathogenesis of inflammatory bowel disease.